{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:09:41Z","timestamp":1793120981588,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-026-07046-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:24:52Z","timestamp":1780129492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of optimized antiretroviral therapy on virological and nutritional outcomes among HIV infected adolescents in Cameroon"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-2108","authenticated-orcid":false,"given":"Calixte Ida","family":"Penda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Epee","family":"Eboumbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Dall\u00e9","family":"Ngondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9 Johanne Nana","family":"Anaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis At\u00e9ba","family":"Ndongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena Mouna","family":"Penda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parfait","family":"Ndengue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juste Patient Mbebi","family":"Enone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritha Mbono","family":"Betoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando Djeudja","family":"Djiyou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Moukoko","family":"Douala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Eposse","family":"Ekoube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassanatou","family":"Iyawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e8le Mangamba Kedy","family":"Koum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole Else Eboumbou","family":"Moukoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"7046_CR1","unstructured":"UNICEF. HIV: adolescent girls still disproportionately affected despite progress. Press release. 2024. Available from https:\/\/www.unicef.fr\/article\/malgre-des-. Cited 2025 Jan 7."},{"key":"7046_CR2","unstructured":"UNICEF. HIV statistics: global and regional trends [Online]. New York: UNICEF. 2024. Available from: https:\/\/data.unicef.org\/topic\/hivaids\/global-regional-trends\/. Cited 2025 Jan 7."},{"issue":"10","key":"7046_CR3","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV Oct. 2018;5(10):e588\u201396.","journal-title":"Lancet HIV Oct"},{"key":"7046_CR4","unstructured":"Ministry of Public Health. Cameroon\u2019s National Strategic Plan for the Fight against HIV\/AIDS and STIs 2021\u20132023 [Online]. National Printing Office, Yaound\u00e9. 2020. Available at: https:\/\/cnls.cm\/wpcontent\/uploads\/2021\/12\/PSN-2021-2023. Cited 2025 Jan 7."},{"key":"7046_CR5","unstructured":"UNAIDS. UNAIDS Country factsheets Cameroon 2020 [Online]. UNAIDS; Available at: https:\/\/aidsinfo.unaids.org. Cited 2025 Jan 7."},{"key":"7046_CR6","unstructured":"Free ONUSIDAS, Free S. AIDS Free \u2013 Cadre pour une acc\u00e9l\u00e9ration accrue de l\u2019action en vue de mettre fin au sida chez les enfants, les adolescents et les jeunes femmes d\u2019ici \u00e0 2020 [Online]. Available at: https:\/\/free.unaids.org\/. Cited 2025 Jan 7."},{"issue":"4","key":"7046_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/FTD.0000000000000637","volume":"41","author":"H Waalewijn","year":"2019","unstructured":"Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, et al. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Therapeutic Drug Monit Aug. 2019;41(4):431\u201343.","journal-title":"Therapeutic Drug Monit Aug"},{"key":"7046_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.11604\/pamj.2021.39.154.27623","volume":"39","author":"M Wandji Lantche","year":"2021","unstructured":"Wandji Lantche M, Fokam J, Nguemedyam Cheudjui AJ, Mbougua Tchatchueng JB, Noumsi TSJ, Ateba Ndongo F, et al. Factors associated with non-adherence to antiretroviral therapy among HIV-infected adolescents aged 15\u201319 years: a snapshot from the Mother and Child Center in Yaounde, Cameroon. Pan Afr Med J. 2021;39:154.","journal-title":"Pan Afr Med J"},{"issue":"10","key":"7046_CR9","doi-asserted-by":"publisher","first-page":"e0276730","DOI":"10.1371\/journal.pone.0276730","volume":"17","author":"CI Penda","year":"2022","unstructured":"Penda CI, Moukoko Mbonjo M, Fokam J, Djeuda ABD, Grace N, Ateba Ndongo F, et al. Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon. PLoS ONE. 2022;17(10):e0276730.","journal-title":"PLoS ONE"},{"issue":"S5","key":"7046_CR10","doi-asserted-by":"publisher","first-page":"e25576","DOI":"10.1002\/jia2.25576","volume":"23","author":"P Rojo","year":"2020","unstructured":"Rojo P, Carpenter D, Venter F, Turkova A, Penazzato M. The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV. J Int AIDS Soc. 2020;23(S5):e25576.","journal-title":"J Int AIDS Soc"},{"issue":"27","key":"7046_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, et al. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"key":"7046_CR12","doi-asserted-by":"crossref","unstructured":"Kouamou V, Manasa J, Katzenstein D, McGregor AM, Ndhlovu CE, Makadzange AT. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy. AIDS. 2019;1(11):1729\u201337.","DOI":"10.1097\/QAD.0000000000002284"},{"key":"7046_CR13","unstructured":"Ministry of Public Health. CNLS Annual Report 2020 [Online]. National Printing Office, Yaound\u00e9. 2020. Available from: https:\/\/cnls.cm\/wpcontent\/uploads\/2021\/12\/rpport-cnls-20202-final-2.pdf. Cited 2025 Jan 7."},{"key":"7046_CR14","unstructured":"Cochran WG. Sampling techniques. 3rd edition. New York (NY). John Wiley and Sons; 1977."},{"key":"7046_CR15","unstructured":"WHO. The role of HIV viral suppression in reducing transmission and improving individual health: policy brief. Gen\u00e8ve, World Health Organization, 2023. Available from: https:\/\/apps.who.int\/iris\/?locale-attribute=fr&. Cited 2025 Jan 7."},{"key":"7046_CR16","unstructured":"World Health Organization. Growth reference data for 5\u201319 years. WHO Reference 2007 [online]. Available from: https:\/\/www.who.int\/tools\/growth-reference-data-for-5to19-years. Cited 2025 Jan 7."},{"issue":"7","key":"7046_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/QAD.0000000000003835","volume":"38","author":"A Devendra","year":"2024","unstructured":"Devendra A, Kohler M, Letsika M, Khooa H, Motaboli L, Lerotholi M, et al. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study. AIDS. 2024;38(7):1013\u201323.","journal-title":"AIDS"},{"issue":"7","key":"7046_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/INF.0000000000003878","volume":"42","author":"JM Bacha","year":"2023","unstructured":"Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J, et al. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023;42(7):576\u201381.","journal-title":"Pediatr Infect Dis J"},{"key":"7046_CR19","doi-asserted-by":"publisher","unstructured":"Konu YR, Takassi E, Peytavin G, Dapam N, Damond F, Oumarou WA et al. Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo. Clin Infect Dis. 2024:ciae278. https:\/\/doi.org\/10.1093\/cid\/ciae278.","DOI":"10.1093\/cid\/ciae278"},{"issue":"1","key":"7046_CR20","doi-asserted-by":"publisher","first-page":"e016512","DOI":"10.1136\/bmjgh-2024-016512","volume":"10","author":"S Desmonde","year":"2025","unstructured":"Desmonde S, Dame J, Malateste K, David A, Amorissani-Folquet M, et al. Disparities in dolutegravir utilisation in children, adolescents and young adults (0\u201324 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort. BMJ Glob Health. 2025;10(1):e016512. https:\/\/doi.org\/10.1136\/bmjgh-2024-016512.","journal-title":"BMJ Glob Health"},{"key":"7046_CR21","doi-asserted-by":"crossref","unstructured":"Fokam J, Billong SC, Jogue F, Moyo Tetang Ndiang S, Nga Motaze AC, Paul KN, et al. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaound\u00e9-Cameroon. PLoS ONE. 2017;12(11):e0187566.","DOI":"10.1371\/journal.pone.0187566"},{"key":"7046_CR22","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Online]. Geneva: World Health Organization. 2013. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/253489. Cited 2025 Jan 7."},{"key":"7046_CR23","unstructured":"World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV [Online]. Geneva: World Health Organization. 2015. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK327115\/. Cited 2025 Jan 7."},{"key":"7046_CR24","unstructured":"World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach\u2009\u2013\u20092010 version [Online]. Geneva: World Health Organization. 2010. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/75236. Cited 2025 Jan 7."},{"key":"7046_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12981-025-00780-2","volume":"22","author":"AA Maghembe","year":"2025","unstructured":"Maghembe AA, Boer MSd, Mtoro MJ, et al. Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis. AIDS Res Ther. 2025;22:82. https:\/\/doi.org\/10.1186\/s12981-025-00780-2.","journal-title":"AIDS Res Ther"},{"issue":"8","key":"7046_CR26","doi-asserted-by":"publisher","first-page":"e0289426","DOI":"10.1371\/journal.pone.0289426","volume":"18","author":"PJ Mb\u00e9bi Enon\u00e9","year":"2023","unstructured":"Mb\u00e9bi Enon\u00e9 PJ, Penda CI, Ngondi G, Fokam J, Ebong SB, Mekoulou Ndongo J, et al. High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon. PLoS ONE. 2023;18(8):e0289426. https:\/\/doi.org\/10.1371\/journal.pone.0289426.","journal-title":"PLoS ONE"},{"key":"7046_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4236\/ijcm.2019.103011","volume":"10","author":"CI Penda","year":"2019","unstructured":"Penda CI, Bissek A-C Z-K, Bilong SC, Boupda L-A, Okala C, At\u00e9ba Ndongo F, et al. Impact of Therapeutic Education on the Viral Load of HIV Infected Children and Adolescents on Antiretroviral Therapy at the Douala Laquintinie Hospital, Cameroon. Int J Clin Med. 2019;10:109\u201321.","journal-title":"Int J Clin Med"},{"issue":"1","key":"7046_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12887-023-03943-0","volume":"23","author":"ABD Djiyou","year":"2023","unstructured":"Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Varloteaux M, de Monteynard LA, Moins C, Moukoko CEE, Aghokeng AF. Viral load suppression in HIV-infected adolescents in Cameroon: towards achieving the UNAIDS 95% viral suppression target. BMC Pediatr. 2023;23(1):119.","journal-title":"BMC Pediatr"},{"issue":"2","key":"7046_CR29","doi-asserted-by":"publisher","first-page":"202193","DOI":"10.1016\/j.jeph.2024.202193","volume":"72","author":"FA Ndongo","year":"2024","unstructured":"Ndongo FA, Kana R, Nono MT, Noah JYA, Ndzie P, Tejiokem MC, et al. Association between mental disorders with detectable viral load and poor adherence to antiretroviral therapy among adolescents infected with Human Immunodeficiency Virus on follow-up at Chantal Biya Foundation, Cameroon. J Epidemiol Popul Health. 2024;72(2):202193.","journal-title":"J Epidemiol Popul Health"},{"issue":"9","key":"7046_CR30","doi-asserted-by":"publisher","first-page":"e0331835","DOI":"10.1371\/journal.pone.0331835","volume":"20","author":"C Nait","year":"2025","unstructured":"Nait C, Ouma S, Ssentongo SM, Oryokot B, Oluka AI, Kusiima R, et al. Prevalence and predictors of viral load non-suppression among adolescents on dolutegravir-based antiretroviral therapy: A cross-sectional study from three urban clinics, Soroti City. PLoS ONE. 2025;20(9):e0331835. https:\/\/doi.org\/10.1371\/journal.pone.0331835.","journal-title":"PLoS ONE"},{"key":"7046_CR31","doi-asserted-by":"crossref","unstructured":"Thivalapill N, Simelane T, Mthethwa N, Dlamini S, Lukhele B, Okello V et al. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021 August 2;73(3):e580\u20136.","DOI":"10.1093\/cid\/ciaa1652"},{"issue":"2","key":"7046_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jpids\/piy139","volume":"9","author":"RM Viani","year":"2020","unstructured":"Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, et al. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents with Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. J Pediatr Infect Dis Soc. 2020;9(2):159\u201365.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"7046_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56\u201363. https:\/\/doi.org\/10.1111\/hiv.12468.","journal-title":"HIV Med"},{"issue":"13","key":"7046_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Gunthard HF, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000001590.","journal-title":"AIDS"},{"issue":"9","key":"7046_CR35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"7046_CR36","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/biomedicines12092083","volume":"12","author":"J Fokam","year":"2024","unstructured":"Fokam J, Bouba Y, Ajeh RA, Guebiapsi DT, Essamba S, Zeh Meka AF, et al. Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study. Biomedicines. 2024;12(9):2083. https:\/\/doi.org\/10.3390\/biomedicines12092083.","journal-title":"Biomedicines"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07046-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:10:19Z","timestamp":1785751819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-07046-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7046"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07046-4","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the Institutional Ethics Committee for Research on Human Health of the University of Douala (reference: (N\u00b0 2992 CEI-UDO \/ 06\/2022 \/ T).) as well as administrative authorizations from the Regional Delegation of Public Health Littoral (N\u00b00175\/AAR\/MINSANTE\/DRSPL\/BCASS) and the management of Laquintinie Hospital in Douala (N\u00b0012\/AR\/MINSANTE\/DHL). Additionally, the research protocol was approved by the local ethics committees of each participating hospital. Prior to inclusion in the study, written informed consent was obtained from all parents or legal guardians of adolescents. For all adolescents, written assent was also obtained in addition to parental consent in accordance with national ethical guidelines before inclusion in the study. Participants were informed about the voluntary nature of their participation and their right to withdraw from the study at any time without prejudice to their clinical care. Confidentiality and anonymity of data were ensured in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"698"}}